3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
11
Observational
2
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
nilotinib
5
dabrafenib
4
Nivolumab
4
Afatinib
4
trametinib
3
regorafenib
3
midostaurin
3
elotuzumab
3
TIC10 compound
3
Sunitinib
3
Prednisone
3
Capecitabine
3
Abiraterone Acetate
3
3-Iodobenzylguanidine
3
venetoclax
2
tucatinib
2
tempol
2
tazemetostat
2
talquetamab
2
talimogene laherparepvec
2
ruxolitinib
2
pomalidomide
2
olaparib
2
niraparib
2
leronlimab
2
lenvatinib
2
ibrutinib
2
gilteritinib
2
ceritinib
2
brexucabtagene autoleucel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Expanded_access
×
ponatinib
×
Clear all
NCT01592136
2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing